Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 522Neoplasms 470Carcinoma, Non-Small-Cell Lung 393Prostatic Neoplasms 302Colorectal Neoplasms 296Lung Neoplasms 259Neoplasm Metastasis 217Ovarian Neoplasms 198Leukemia, Myeloid, Acute 194Pancreatic Neoplasms 185Multiple Myeloma 172Squamous Cell Carcinoma of Head and Neck 133Recurrence 132Stomach Neoplasms 129Brain Neoplasms 126Melanoma 123Carcinoma, Hepatocellular 123Endometrial Neoplasms 120Glioblastoma 118Triple Negative Breast Neoplasms 111Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Hematologic Neoplasms 99Head and Neck Neoplasms 97Carcinoma, Renal Cell 96Lymphoma 93Urinary Bladder Neoplasms 90Sarcoma 90Glioma 88Lymphoma, Large B-Cell, Diffuse 81Small Cell Lung Carcinoma 80

Interventions

atezolizumab 1Hydroxyurea 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Treatment-Refractory Solid Tumors × 90 days × Clear all
NCT07190833 2026-04-09

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

Bionoxx Inc.

Phase 1 Recruiting
27 enrolled
Other solid neoplasm

Treatment-Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡